Small molecule · Modulator of Hemoglobin subunit beta (hemoglobin S) (HBB) · developed by Pfizer
Osivelotor is an orally bioavailable agent that covalently binds sickle cell hemoglobin S (HbS). It stabilizes hemoglobin in its oxygenated state, which increases oxygen affinity and inhibits HbS polymerization and red blood cell sickling. It is being studied in sickle cell disease.
Summary written with AI from the sources listed at the end of this page.
Healthy
Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →